My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 10 680 / https://doi.org/10.3332/ecancer.2016.680

Clinical Study

Repurposing Drugs in Oncology (ReDO)—Propranolol as an anti-cancer agent

Propranolol (PRO) is a well-known and widely used non-selective beta-adrenergic receptor antagonist (beta-blocker), with a range of actions which are of interest in an oncological context. PRO displays effects on cellular proliferation and invasion, on the immune system, on the angiogenic cascade, and on tumour cell sensitivity to existing treatments. Both pre-clinical and clinical evidence of these effects, in multiple cancer types, is assessed and summarised and relevant mechanisms of action outlined. In particular there is evidence that PRO is effective at multiple points in the metastatic cascade, particularly in the context of the post-surgical wound response. Based on this evidence the case is made for further clinical investigation of the anticancer effects of PRO, particularly in combination with other agents. A number of trials are on-going, in different treatment settings for various cancers.

Keywords: Propranolol, beta-blockers, drug repurposing, ReDO project

Loading Article Metrics ... Please wait

Author interviews

Pan Pantziarka and Lydie Meheus

Anticancer Fund, Belgium

Related videos

Related articles

Case Report: Primary non-Hodgkin lymphoma of the prostate: a case report

Abstract | Full Article | PDF Published: 12 Dec 2017 / https://doi.org/10.3332/ecancer.2017.789

Clinical Study: Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents

Abstract | Full Article | PDF Published: 23 Nov 2017 / https://doi.org/10.3332/ecancer.2017.781

Clinical Study: Laparoscopic liver resection in metastatic colorectal cancer treatment: comparison with long-term results using the conventional approach

Abstract | Full Article | PDF Published: 24 Oct 2017 / https://doi.org/10.3332/ecancer.2017.775

Research: Frozen section evaluation of sentinel lymph nodes in breast carcinoma: a retrospective analysis

Abstract | Full Article | PDF Published: 18 Oct 2017 / https://doi.org/10.3332/ecancer.2017.774

Case Report: Functional pancreatic neuroendocrine tumour causing Cushing’s syndrome: the effect of chemotherapy on clinical symptoms

Abstract | Full Article | PDF Published: 13 Oct 2017 / https://doi.org/10.3332/ecancer.2017.773



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence